Study Data from Antwerp University Hospital Provide New Insights into Marfan Syndrome (Investigation of Strategies to Block Downstream Effectors of AT1R-Mediated Signalling to Prevent Aneurysm Formation in Marfan Syndrome).

A recent study conducted at Antwerp University Hospital in Belgium explored strategies to prevent aneurysm formation in Marfan syndrome (MFS) patients. The researchers found that angiotensin II receptor blockers (ARBs) can slow down aortic dilation in MFS mouse models, but they only have a limited effect in human patients. The study investigated the targeting of b-arrestin signaling in MFS mice using TRV027, as well as the combination of lower doses of losartan with barbadin and DMX20. However, none of these interventions showed a significant beneficial effect on aneurysm advancement. The researchers concluded that complete blockade of AT1R function, achieved through high-dose losartan administration, may be necessary to inhibit aneurysm progression in MFS. [Extracted from the article]